Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Michael Castor’s Sio Capital Management’s New Bets For This Quarter

#2 Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP)

– Shares Owned by Sio Capital (as of December 31): 291,877

– Value of Holding (as of December 31): $9.13 Million

Since its IPO in November, shares of the $1.29 billion radiopharmaceutical company are up by more than 36%. The company’s lead drug, Lutathera, treats midgut neuroendocrine tumors (NETs). The drug met its primary endpoint in Phase 3 trials and has also shown promising results in the Interim OS analysis. Moreover, Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP) also received an extension on its Prescription Drug User Fee Act (PDUFA) date for its Priority Review of the Company’s New Drug Application (NDA) for Somakit-TATE, which is used in neuroendocrine tumor diagnosis. Among the funds we track, Phill Gross and Robert Atchinson‘s Adage Capital is the largest shareholder of Advanced Accelerator Application SA (ADR) (NASDAQ:AAAP) with about 1.23 million shares valued at $38.46 million.

#1 McKesson Corporation (NYSE:MCK)

– Shares Owned by Sio Capital (as of December 31): 56,000

– Value of Holding (as of December 31): $11.05 Million

Sio’s stake McKesson Corporation (NYSE:MCK) represents 4.89% of the fund’s equity portfolio. The stock price of the San Francisco-based drug distributor and provider of technology solutions has fallen by more than 32% over the last 52 weeks, despite gaining 11% during the fourth quarter. The company recently acquired two cancer-care companies, Biologics and Vantage Oncology for $1.2 billion. Moody’s sees the deal as credit positive and expects financial leverage to remain the same, while McKesson expands its reach in specialty services. Parsa’s Kiai‘s Steamboat CApital Partners purchased some 94,300 shares of McKesson Corporation (NYSE:MCK) during the fourth quarter.

Follow Mckesson Corp (NYSE:MCK)
Trade (NYSE:MCK) Now!

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.